Skip Navigation



Human Molecular Genetics Advance Access published online on March 27, 2008

Human Molecular Genetics, doi:10.1093/hmg/ddn100
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
17/13/2030    most recent
ddn100v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Beysen, D.
Right arrow Articles by De Baere, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beysen, D.
Right arrow Articles by De Baere, E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Missense mutations in the forkhead domain of FOXL2 lead to subcellular mislocalisation, protein aggregation and impaired transactivation

Diane Beysen1,+, Lara Moumné2,3,4,+, Reiner Veitia2,3,4,5, Hartmut Peters6, Bart P. Leroy1,7, Anne De Paepe1 and Elfride De Baere1,*

1 Center for Medical Genetics, Ghent University Hospital, 9000 Ghent, Belgium 2 INSERM U567, Team21, Genetics and Development Department, Institut Cochin, 24 rue du Faubourg St-Jacques, 75014, Paris, France 3 CNRS UMR8104, Institut Cochin, 24 rue du Faubourg St-Jacques, 75014, Paris, France 4 Université Paris Descartes, Faculté de Médecine Cochin-Port-Royal, 24 rue du Faubourg St-Jacques, 75014, Paris, France 5 Université Denis Diderot, Paris VII, 75014 Paris, France 6 Institute of Medical Genetics, Charité - Universitätsmedizin Berlin, Berlin, Germany 7 Department of Ophthalmology, Ghent University Hospital, 9000 Ghent, Belgium

* Correspondence to: Elfride.DeBaere{at}UGent.be Center for Medical Genetics, Ghent University Hospital, De Pintelaan 185, B- 9000 Ghent, Belgium, Phone: 32-9-332.5186. Fax: 32-9-332.4970

Received February 20, 2008; Revised March 25, 2008; Accepted March 25, 2008

Mutations of the FOXL2 gene have been shown tocause blepharophimosis syndrome (BPES), characterised by an eyelid malformation associated with premature ovarian failure or not. Recently, polyalanine expansions and truncating FOXL2 mutations have been shown to lead to protein mislocalisation, aggregation and altered transactivation. Here, we study the molecular consequences of 17 naturally-occurring FOXL2 missense mutations. Most of them map to the conserved DNA-binding forkhead domain (FHD). The subcellular localisation and aggregation pattern of the mutant FOXL2 proteins in COS-7 cells was variable and ranged from a diffuse nuclear distribution like the wild-type to extensive nuclear aggregation often in combination with cytoplasmic mislocalisation and aggregation. We also studied the transactivation capacity of the mutants in FOXL2 expressing granulosa-like cells (KGN). Several mutants led to a loss-of-function, while others are suspected to induce a dominant negative effect. Interestingly, one mutant that is located outside the FHD (S217F), appeared to be hypermorphic and had no effect on intracellular protein distribution. This mutation gives rise to a mild BPES phenotype. In general, missense mutations located in the FHD lead to classical BPES and cannot be correlated with expression of the ovarian phenotype. However, a potential predictive value of localisation and transactivation assays in the making of genotype-phenotype correlations is proposed. This is the first study to demonstrate that a significant number of missense mutations in the FHD of FOXL2 lead to mislocalisation, protein aggregation and altered transactivation, and to provide insights into the pathogenesis associated with missense mutations of FOXL2 in human disease.


+ These authors contributed equally to this work.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Hum ReprodHome page
G. Meduri, A. Bachelot, C. Duflos, B. Bstandig, C. Poirot, C. Genestie, R. Veitia, E. De Baere, and P. Touraine
FOXL2 mutations lead to different ovarian phenotypes in BPES patients: Case Report
Hum. Reprod., October 9, 2009; (2009) dep355v1.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
A. Dipietromaria, B. A. Benayoun, A.-L. Todeschini, I. Rivals, C. Bazin, and R. A. Veitia
Towards a functional classification of pathogenic FOXL2 mutations using transactivation reporter systems
Hum. Mol. Genet., September 1, 2009; 18(17): 3324 - 3333.
[Abstract] [Full Text] [PDF]


Home page
MutagenesisHome page
Y. Xu, H. Lei, H. Dong, L. Zhang, Q. Qin, J. Gao, Y. Zou, and X. Yan
FOXL2 gene mutations and blepharophimosis-ptosis-epicanthus inversus syndrome (BPES): a novel mutation detected in a Chinese family and a statistic model for summarizing previous reported records
Mutagenesis, September 1, 2009; 24(5): 447 - 453.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
B. A. Benayoun, F. Batista, J. Auer, A. Dipietromaria, D. L'Hote, E. De Baere, and R. A. Veitia
Positive and negative feedback regulates the transcription factor FOXL2 in response to cell stress: evidence for a regulatory imbalance induced by disease-causing mutations
Hum. Mol. Genet., February 15, 2009; 18(4): 632 - 644.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.